Abstract
In 1908 phenytoin (5,5-diphenylhydantoin) was first synthesized as a barbiturate derivative in Germany by professor Heinrich Biltz (1865–1943) and subsequently resynthesized by an American chemist of the pharmaceutical company Parke-Davis in 1923 in Detroit. Screening phenytoin did not reveal comparable sedative side effects as barbiturates and, thus, Parke-Davis discarded this compound as a useful drug. In 1936, phenytoin’s anticonvulsive properties were identified via a new animal model for convulsive disorders, developed by Putnam and Merritt, who also evaluated its clinical value in a number of patients in the period 1937–1940. For many diseases, mechanism of action of phenytoin remains obscure. The voltage-gated sodium channel was and is generally regarded as the main target to explain phenytoin’s activity as an anticonvulsant and an anti-arrhythmic drug. This target, however, does not explain many of the other clinical properties of phenytoin. We will explore a number of original articles on phenytoin published in its 80 years history and give extra attention to the various hypothesis and experiments done to elucidate its mechanisms of action. Phenytoin has been explored in over 100 different disorders; the last two promising indications tested in the clinic are breast cancer and optic neuritis. Most probably, there are multiple targets active for these various disorders, and the insight into which targets are relevant is still very incomplete. It is remarkable that many pharmacological studies tested one dose only, mostly 50 or 100 μM, doses which most probably are higher than the non-plasma bound phenytoin plasma levels obtained during treatment.
Similar content being viewed by others
References
Anderson RJ, Development TLCTCHPCDDa (2009) The little compound that could: how phenytoin changed drug discovery and development. Mol Interv 9:208–214
Putnam TJ, Merritt HH (1937) Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85(2213):525–526. doi:10.1126/science.85.2213.525
Friedlander WJ (1986) Putnam, Merritt, and the discovery of Dilantin. Epilepsia 27(3):S1–20
Yang M, Kozminski DJ, Wold LA, Modak R, Calhoun JD, Isom LL, Brackenbury WJ (2012) Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res Treat 134(2):603–615. doi:10.1007/s10549-012-2102-9
Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–269. doi:10.1016/S1474-4422(16)00004-1
Wang Y, Ying X, Chen L, Liu Y, Liang J, Xu C, Guo Y, Wang S, Hu W, Du Y, Chen Z (2016) Electroresponsive nanoparticles improve antiseizure effect of phenytoin in generalized tonic-clonic seizures. Neurotherapeutics. doi:10.1007/s13311-016-0431-9
Shorvon SD (2009) Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909–1958. Epilepsia 3:69–92
Hauptmann A (1912) Luminal bei Epilepsie. Münch Med Wochenschr 59:1907–1909
Spiegel E, Wycis H (1940) Convulsive reactivity in hypercholesteremia. Confin Neurol 3(1–2):262–265
Aird RB, Gurchot C (1939) Protective effect of cholesterol in experimental epilepsy. Arch Neurol Psychiatry 42(3):491–506
Aird RB (1939) Mode of action of brilliant vital red in epilepsy. Arch Neurol Psychiatry 42(4):700–723
McQuarrie I (1940) The physicochemical approach to the mechanisms of convulsive reactivity. In: Visscher MB (ed) Chemistry and medicine. University of Minnesota Press, Minneapolis, pp 225–250
Merritt H, Putnam TJ (1938) Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J Am Med Assoc 111(12):1068–1073. doi:10.1001/jama.1938.02790380010004
Merritt H, Putnam TJ (1938) A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry 39(5):1003–1015. doi:10.1001/archneurpsyc.1938.02270050129007
Merritt H, Putnam TJ (1939) Sodium diphenyl hydantoinate in treatment of convulsive seizures: toxic symptoms and their prevention. Arch Neurol Psychiatry 42(6):1053–1058. doi:10.1001/archneurpsyc.1939.02270240091005
Putnam TT (1939) USe of sodium diphenyl hydantoinate as anticonvulsant. J Am Med Assoc 112(21):2190. doi:10.1001/jama.1939.02800210084024
Merritt H, Putnam TJ (1940) Further experiences with the use of sodium diphenyl hydantoinate in the treatment of convulsive disorders. Am J Psychiatry 96(5):1023–1027. doi:10.1176/ajp.96.5.1023
Lennox WG (1938) A new remedy for epilepsy? Lancet 232(6018):1544
Kimball O (1939) The treatment of epilepsy with sodium diphenyl hydantoinate. J Am Med Assoc 112(13):1244–1245. doi:10.1001/jama.1939.02800130028009
Bonafede VI, Nathan RE (1940) The treatment of epilepsy with sodium diphenyl hydantoinate. Psychiatr Q 14(3):603–611. doi:10.1007/bf01573141
Frankel SI (1940) Dilantin sodium in the treatment of epilepsy. J Am Med Assoc 114(14):1320–1321. doi:10.1001/jama.1940.02810140020005
Fetterman JL (1940) Dilantin sodium therapy in epilepsy: report of study in progress. J Am Med Assoc 114(5):396–400. doi:10.1001/jama.1940.02810050016004
Robinson LJ, Osgood R (1940) Comparative effects of phenobarbital and dilantin sodium: in the treatment of epilepsy. J Am Med Assoc 114(14):1334–1335. doi:10.1001/jama.1940.02810140034009
Blair D (1940) The modern treatment of epilepsy: a critical survey, with special reference to sodium diphenyl hydantoinate and a comparison of its effects with those of other anticonvulsants. Br J Psychiatry 86(364):888–927. doi:10.1192/bjp.86.364.888
Williamson BAM (1940) Severe toxic effects of sodium diphenyl hydantoinate in mentally defective epileptics. Br J Psychiatry 86(364):981–987. doi:10.1192/bjp.86.364.981
Firmino F, de Almeida AM, e Silva Rde J, Alves Gda S, Grandeiro Dda S, Penna LH (2014) Scientific production on the applicability of phenytoin in wound healing. Rev Esc Enferm USP 48(1):166–173
Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ (1984) Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 228(2):523–530
Morello RS, Begenisich T, Yeh JZ (1984) Determination of the active form of phenytoin. J Pharmacol Exp Ther 230(1):156–161
Yeh JZ, Quandt FN, Kirsch GE (1981) Comparative studies of phenytoin action on ionic channels in excitable membranes. Fed Proc 40(31):20
Rall TW, Schleiffer L (1985) Drugs effective in the treatment of the epilepsies. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 7th edn. Macmillan, New York, pp 446–472
Handzlik J, Maciag D, Kubacka M, Mogilski S, Filipek B, Stadnicka K, Kiec-Kononowicz K (2008) Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin. Bioorg Med Chem 16(11):5982–5998. doi:10.1016/j.bmc.2008.04.058
Fadiel A, Song J, Tivon D, Hamza A, Cardozo T, Naftolin F (2015) Phenytoin is an estrogen receptor alpha-selective modulator that interacts with helix 12. Reprod Sci 22(2):146–155. doi:10.1177/1933719114549853
Patejdl R, Leroux AC, Noack T (2015) Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil 27(10):1453–1465. doi:10.1111/nmo.12645
Suzuki AM, Yoshimura A, Ozaki Y, Kaneko T, Hara Y (2009) Cyclosporin A and phenytoin modulate inflammatory responses. J Dent Res 88(12):1131–1136. doi:10.1177/0022034509350566
Handzlik J, Szymanska E, Nedza K, Kubacka M, Siwek A, Mogilski S, Filipek B, Kiec-Kononowicz K (2011) Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to alpha 1-adrenergic receptors among arylpiperazine derivatives of phenytoin. Bioorg Med Chem 19(3):1349–1360. doi:10.1016/j.bmc.2010.11.051
Cobos EJ, Baeyens JM, Del Pozo E (2005) Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 55(3):192–195. doi:10.1002/syn.20103
Tunnicliff G (1996) Basis of the antiseizure action of phenytoin. Gen Pharmacol 27(7):1091–1097
Holopainen IE, Kivela R, Korpi ER (2001) Do antiepileptics phenytoin, carbamazepine, and loreclezole show GABA(A) receptor subtype selectivity in rat brain sections? Neurochem Res 26(1):89–94
Wong PT, Teo WL (1988) Properties of phenytoin binding sites in the rat brain: regional distribution and postnatal development. Jpn J Pharmacol 46(3):261–266
Eijkelkamp N, Linley JE, Baker MD, Minett MS, Cregg R, Werdehausen R, Rugiero F, Wood JN (2012) Neurological perspectives on voltage-gated sodium channels. Brain 135(Pt 9):2585–2612
Kuo CC (1998) A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 54(4):712–721
Lucas PT, Meadows LS, Nicholls J, Ragsdale DS (2005) An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res 64(3):77–84. doi:10.1016/j.eplepsyres.2005.03.003
Colombo E, Franceschetti S, Avanzini G, Mantegazza M (2013) Phenytoin inhibits the persistent sodium current in neocortical neurons by modifying its inactivation properties. PLoS One 8(1):e55329. doi:10.1371/journal.pone.0055329
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors are holders of two patents: Topical phenytoin for use in the treatment of peripheral neuropathic pain and topical pharmaceutical composition containing phenytoin and a (co-)analgesic for the treatment of chronic pain.
Rights and permissions
About this article
Cite this article
Keppel Hesselink, J.M., Kopsky, D.J. Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. J Neurol 264, 1617–1621 (2017). https://doi.org/10.1007/s00415-017-8391-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-017-8391-5